Trial reportHeart and vessels2014
Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
Trial report in Heart and vessels, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Effects of Xinnaoning combined with trimetazidine on the levels of CK and its isoenzymes, AST, ALT and LDH in patients with myocardial ischemia.American journal of translational research · 2021Article
- The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction.The Korean journal of internal medicine · 2019Article
- Application of self-care based on full-course individualized health education in patients with chronic heart failure and its influencing factors.World journal of clinical cases · 2019Article
- Effect of carvedilol on heart rate response to cardiopulmonary exercise up to the anaerobic threshold in patients with subacute myocardial infarction.Heart and vessels · 2019Article
- Are patients in heart failure trials representative of primary care populations? A systematic review.BJGP open · 2018Article
- Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Article
- Efficacy of Intravenous Administration of Landiolol in Patients With Acute Heart Failure and Supraventricular Tachyarrhythmia.Journal of clinical medicine research · 2017Article
- Is cardiopulmonary exercise testing essential to indicate ventricular assist device implantation in patients with INTERMACS profile 4-7?Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2016Article
- Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.JACC. Heart failure · 2016Review
- Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy.Heart and vessels · 2016Observational
- Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure.Heart and vessels · 2016Observational
- Lower rotation speed stimulates sympathetic activation during continuous-flow left ventricular assist device treatment.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2015Article
- Seasonal variation in patients with acute heart failure: prognostic impact of admission in the summer.Heart and vessels · 2015Article
- Preoperative beta-blocker treatment is a key for deciding left ventricular assist device implantation strategy as a bridge to recovery.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF). However, few studies have compared its efficacy and safety with those of the widely used β-blocker carvedilol in Japanese patients with CHF. We designed a confirmatory trial of bisoprolol using carvedilol as a control drug; however, the trial was discontinued after an off-label use of bisoprolol was approved during the study. Bisoprolol and carvedilol were administered for 32 weeks in 31 and 28 patients, respectively. The mean maintenance doses of bisoprolol and carvedilol were 3.3 and 13.6 mg/day, respectively, and the mean durations of treatment were 188.2 and 172.9 days, respectively. Heart-rate changes were similar in both groups. The mean changes from baseline to Week 32 in left ventricular (LV) ejection fraction (EF) (bisoprolol vs carvedilol groups; 11.7 % ± 8.6 % vs 10.1 % ± 10.5 %), LV end-diastolic volume (-37.5 ± 48.7 vs -24.7 ± 29.4 ml), and LV end-systolic volume (-41.9 ± 43.0 vs -29.3 ± 25.9 ml) revealed a decrease in LV volume and an increase in LVEF in both groups. The cumulative event-free rate for a composite of cardiovascular death or admissions to hospital for worsening of CHF was 92.4 % and 94.7 % in the bisoprolol and carvedilol groups, respectively. Overall, 90.3 % and 85.7 % of patients were titrated up to the maintenance doses of bisoprolol and carvedilol, respectively. Bisoprolol, at half the dose used in other countries, is well tolerated and is as effective as carvedilol for treating Japanese patients with mild to moderate CHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.